MeiraGTx Holdings plc (MGTX)
After hours:
| Previous Close | 4.9100 |
| Open | 4.8800 |
| Bid | 4.8500 x 200 |
| Ask | 4.9000 x 200 |
| Day's Range | 4.7900 - 4.9900 |
| 52 Week Range | 3.4900 - 8.3500 |
| Volume | |
| Avg. Volume | 149,191 |
| Market Cap | 313.816M |
| Beta (5Y Monthly) | 1.27 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- GlobeNewswire
MeiraGTx to Participate in Upcoming Investor Conferences
LONDON and NEW YORK, April 24, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (NASDAQ: MGTX), a vertically integrated, clinical stage gene therapy company, today announced that Alexandria Forbes, Ph.D., President and Chief Executive Officer, will participate in the following investor conferences: Chardan 8th Annual Genetic Medicines and Cell Therapy Manufacturing Summit, Virtual Corporate presentation: Monday, April 29, 2024, at 11:00 a.m. ET BofA Securities Healthcare Conference 2024, Las Vegas
- GlobeNewswire
MeiraGTx Announces Oral Presentation at the 2024 American Academy of Oral Medicine (AAOM) Annual Conference
LONDON and NEW YORK, April 18, 2024 (GLOBE NEWSWIRE) -- MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage gene therapy company, today announced the Company gave an oral presentation at the American Academy of Oral Medicine Annual Conference, being held from April 16-20, 2024, at the Hyatt Regency Grand Cypress in Orlando, FL. The details of the oral presentation are below: Session: Oral Abstract Session IPresentation ID #196Title: Results of a Phase 1, Open-label, Dos
- GlobeNewswire
MeiraGTx Reports Fourth Quarter and Full Year 2023 Financial and Operational Results and Recent Business Updates
- Company aligned with FDA on requirements for ongoing Phase 2 AQUAx2 clinical trial for Grade 2/3 radiation-induced xerostomia to be considered pivotal supporting potential BLA filing - Company to present data from the Phase 1 AQUAx study in an oral presentation at the American Academy of Oral Medicine 2024 annual meeting (AAOM) April 17-20, 2024 - Completed dosing the three-arm randomized, sham-controlled Phase 1 clinical bridging study for AAV-GAD for the treatment of Parkinson’s disease - Co
